Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

Abstract: Polynucleotides encoding fusion proteins comprising fragments of toxin A and toxin B from Clostridium difficile are described, as well as vectors and host cells containing such polynucleotides.

Abstract: The present invention provides antibodies that bind to human gremlin-1 (GREM1), and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to GREM1. The antibodies of the invention are useful for inhibiting or neutralizing GREM1 activity, thus providing a means of treating a GREM1-related disease or disorder such as fibrosis and cancer. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of fibrosis of the liver, lungs or kidney.

Abstract: Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.

Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).

Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.

Abstract: Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

Abstract: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.

Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.

Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.

Abstract: The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.

Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.

Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Abstract: 1. An esterified cellulose ether which i) comprises groups of the formula —C(O)—R—COOH or a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOH, wherein R is a divalent hydrocarbon group, ii) has a weight average molecular weight Mw of up to 70,000 Dalton, iii) has a degree of neutralization of the groups —C(O)—R—COOH of not more than 0.4, and iv) has a solubility in water of at least 2.0 weight percent at 2° C., is useful for preparing enteric capsules.

Abstract: The present invention relates to a novel Group 4 transition metal compound, a method for preparing the compound, a catalyst composition comprising the compound, and a method for preparing a polyolefin comprising performing a polymerization reaction of olefin monomers, in the presence of the catalyst composition. Since the Group 4 transition metal compound of the present invention exhibits an excellent catalytic activity in polyolefin synthesis reactions, as well as having excellent thermal stability, it can be used for polyolefin synthesis reactions at high temperatures, and by changing the type of a central metal and ligand, the weight average molecular weight of synthesized polyolefins and the octene content in the polymer can be controlled. Therefore, it can be effectively used in polyolefin synthesis processes in which grades are controlled.

Abstract: An antibody-drug conjugate having a cyclic benzylidene acetal linker represented by formula (1) or formula (2), wherein Y is an antibody; D is a drug; R1 and R6 are each independently a hydrogen atom or a hydrocarbon group; R2, R3, R4 and R5 are each independently an electron-withdrawing or electron-donating substituent or a hydrogen atom; s is 1 or 2, t is 0 or 1, and s+t is 1 or 2; w is an integer of 1 to 20; and Z1 and Z2 are each independently a selected divalent spacer:

Abstract: Provided is a resin composite material in which a carbon material with a graphene structure is dispersed in a synthetic resin and which has a high mechanical strength and a low linear expansion coefficient and a method for producing the resin composite material. A resin composite material contains a synthetic resin and a carbon material with a graphene structure dispersed in the synthetic resin, wherein the synthetic resin is grafted onto the carbon material and the grafting ratio thereof onto the carbon material is 5% to 3300% by weight. A method for producing a resin composite material includes the steps of: preparing a resin composite containing a synthetic resin and a carbon material with a graphene structure dispersed in the synthetic resin; and grafting the synthetic resin onto the carbon material concurrently with or after the step of preparing the resin composite.

Abstract: Solid adducts comprising MgCl2, ethanol and water characterized in that the amount of ethanol ranges from 50% to less than 57% by weight, the amount of water is ranges from 0.5 to 5% by weight, the ethanol/water weight ratio is lower than 60 and the porosity determined with Hg method due to pores with radius up to 1 ?m and expressed in cm3/g, is lower than 0.2.

Abstract: Provided are novel ethylene acid copolymers, their ionomers and their use in various articles, including packaging films and injection molded articles. The ethylene acid copolymers comprise copolymerized units of ethylene, about 10 to about 30 wt % of copolymerized units of a first ?,?-unsaturated carboxylic acid having 3 to 10 carbon atoms; and about 5 to about 15 wt % of copolymerized units of a derivative of a second ?,?-unsaturated carboxylic acid having 3 to 10 carbon atoms. Preferred derivatives include esters, and in particular alkyl esters. These ethylene acid copolymers and ionomers have improved optical properties when compared to conventional ethylene acrylic or methacrylic acid copolymers and their ionomers.

Abstract: A process including contacting one or more monomers, at least one catalyst system, and a condensing agent including a majority of 2,2-dimethylpropane under polymerizable conditions to produce a polyolefin polymer is provided.

Abstract: A polymer comprising recurring units derived from vinylanthraquinone, recurring units containing a benzene ring having a hydroxyl-bearing tertiary alkyl group bonded thereto, and recurring units derived from hydroxystyrene is provided. The polymer is used as a base resin to formulate a negative resist composition having a high resolution and minimal LER.

Abstract: The invention pertains to a method for emulsion polymerization of at least one fluoromonomer, said method comprising: (i) providing at least one aqueous emulsion comprising at least one surfactant and a monomer mixture [mixture (M)] comprising at least one fluoromonomer [monomer (F)] and optionally at least one additional monomer, and at least one RAFT/MADIX agent; (ii) initiating the polymerization of said monomer mixture in said aqueous emulsion adding at least one radical initiator; (iii) continuing the polymerization by adding additional amounts of said mixture (M) and said RAFT/MADIX agent, until converting the targeted amount of said mixture (M), and (iv) terminating the polymerization and recovering a latex of fluoropolymer [polymer (F)]; wherein the amount of RAFT/MADIX agent is comprised between 0.1 and 0.

Abstract: A composition results from the mixture of at least one copolymer A resulting from the copolymerization of at least one monomer functionalized by diol functions and at least one compound A2 comprising at last two boronic ester functions. They have rheological properties which are very varied according to the proportion of the A1 and A2 compounds used. The field is that of associative and exchangeable polymers.

Abstract: A graft-modified propylene.?-olefin copolymer (A) is obtained by graft-reacting a polar monomer onto a propylene.?-olefin copolymer (a) including 50 to 90 mol % of propylene-derived structural units (C3) and 10 to 50 mol % of C4-8 ?-olefin-derived structural units (C?) (wherein the total of the structural units C3 and C? is 100 mol %), and satisfies the following requirements (i) to (iv) at the same time: (i) the amount of the polar monomer grafted is 0.4 to 1.5 wt %, (ii) the content of the polar monomer is not more than 1000 ppm, (iii) the content of a gel insoluble in xylene at 140° C. is not more than 2.5 wt %, and (iv) the content of a volatile hydrocarbon compound is not more than 10 ppm.

Abstract: The present disclosure is directed to improved poly(arylene ether ketone) powders for use in laser sintering, powder coating, compression molding, or transfer molding.

Abstract: The present invention relates to improved hydrogel materials using water gellants that are comprised of polymer backbones P to which hydrogen bonding 4H-units are covalently attached via a hydrophobic linker L. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical performance and function and are especially suitable for biomedical applications.

Abstract: Polymeric reaction products of certain aromatic alcohols with certain diaryl-substituted aliphatic alcohols are useful as underlayers in semiconductor manufacturing processes.

Abstract: An ion conducting and electron conducting polymer is comprised of a first polymer of a single-sulfonic acid polymer or a multi-sulfonic acid polymer and a second polymer of an EDOT analog monomer having the following formula: wherein z=O or S; Y2=—COH, —C6H13, or —COOH; a=0 or 1; Y3=—CH3, —C2H5, —CH2C6H6, —C6H13, —C8H17, —CH2OC6H13, or —CH2OC6H6; and b=0 or 1; wherein a sulfonic acid group of each branch of the first polymer electronically interacts with one or more thiophene rings of the second polymer; and wherein any remaining sulfonic acid groups on each branch of the first polymer are converted to SO3Li.

Abstract: Compositions comprising stereocomplexes of enantiomeric polymer chains having individual repeat units formed from the reaction of an epoxide and cyclic anhydride. The compositions can be made by mixing two types of enantiomeric polymer chains having opposite absolute stereochemistry. The compositions can be used in applications such as biomedical applications and drug delivery applications.

Abstract: A resin does not need to incorporate a fluorescent substance and exhibits fluorescence itself. Also, a liquid crystal polymer is provided which does not contain a bleeding out substance such as hydrophobic silica and barium sulfate and which has an effect of suppressing fibrillation in the resin itself. A liquid crystal polymer includes a copolymer of a polymerizable monomer (A) selected from the group consisting of pyromellitic acid or anhydride thereof and a reactive derivative thereof and a polymerizable monomer (B).

Abstract: Described are shape-memory polymers that have a branched or telechelic prepolymer having a low polydispersity crosslinked with a stoichiometric amount of a multifunctional crosslinker. Also described are methods of making shape-memory polymers by crosslinking a stoichiometric amount of a multifunctional crosslinker with a branched or telechelic prepolymer having a low polydispersity. Methods of measuring the energy storage capacity of a shape-memory polymer are also disclosed.

Abstract: A process to prepare a polyester polymer composition comprising a polyester polymer having furanic units is disclosed. The process comprises a step of ring-opening polymerization of a cyclic polyester oligomer, which comprises residue of furandicarboxylic acid and a diol, in the presence of a catalyst in order to yield a polyester polymer having furanic units. The polyester polymer composition obtainable by the process, wherein the polyester polymer composition comprises a polyester polymer having furanic units and a cyclic polyester oligomer in a concentration of less than 5 wt % of the composition. The use of the polyester polymer composition in extrusion, injection molding, or blow molding are also disclosed.

Abstract: A process for preparing polybutylene terephthalate (PBT) which includes step of melting solid PBT oligomer having an IV of between 0.13 and 0.17 dL/g and a CEG of between 90 and 180 mmol/kg; and further step of the PBT oligomer polycondensation; wherein the polycondensation process is carried out continuously using a melt tank for melting oligomers, one or more reactors for post-condensation processing, and one or more finishing reactors to increase molecular weight. The resulting PBT has an intrinsic viscosity (IV) of between 0.5 and 1.3 dl/g and a carboxylic end group (CEG) concentration of between 1 and 75 mmol/kg.

Abstract: The invention is directed to processes for preparation of oxetane polymers, wherein an epoxide accelerant is reacted with one or more equivalents of a 3-monosubstituted oxetane or a 3,3-disubstituted oxetane, wherein the epoxide accelerant is selected from the group consisting of 2,2-substituted epoxide, 2,2,3-substituted epoxide, 2,2,3,3-substituted epoxide, and mixtures thereof. Also disclosed are oxetane polymers prepared by the processes of the invention.

Abstract: The invention relates to a composition for thermoplastic composite material comprising: 30% to 60% by volume, preferentially 35% to 50% by volume, of a thermoplastic matrix comprising from 50% to 100% by weight of a semi-crystalline polyamide polymer and from 0% to 50% by weight of at least one additive and/or of at least one other polymer, 40% to 70% by volume, preferentially 50% to 65% by volume, of long reinforcing fibers (or of long fibrous reinforcement), said thermoplastic matrix impregnating said long reinforcing fibers (or said long fibrous reinforcement), said semi-crystalline polyamide polymer being: a) a reactive composition comprising or consisting of at least one reactive polyamide prepolymer which is a precursor of said semi-crystalline polyamide polymer, or, as an alternative to a), b) a nonreactive composition of at least one polyamide polymer, said composition being that of said thermoplastic matrix defined above, and said reactive polyamide prepolymer of the composition a) and said pol

Abstract: The present invention relates to thermoplastic polyamides (PA) comprising recurring units derived from a PFPE dicarboxylic acid (PFPA-DA) or a PFPE diamine (PFPE-NN) in a defined weight amount with respect to other units derived from the other monomers used in the course of polymerization. Polyamides (PA) are endowed with improved surface properties, chemical resistance and reduced brittleness and do not require the addiction of impact modifiers.

Abstract: A thermoplastic composition includes a poly(etherimide-siloxane) copolymer having a siloxane content of more than 0 to less than 50 weight percent based on the total weight of the poly(etherimide-siloxane) copolymer; an aromatic polyketone; and a mineral filler having a particle diameter of 0.1-2 micrometers. The thermoplastic composition has a lower toxicity index than the same composition without the aromatic polyketone, the mineral filler, or both, as determined in accordance with EN53505.

Abstract: Disclosed herein is a friable polyimide powder having a weight average molecular weight, as determined by gel permeation chromatography (GPC) using polystyrene standards, of less than or equal to 24,500 Daltons and a reactive aromatic amine end group concentration greater than or equal to 3 mole percent, wherein 90 weight percent of the powder particles are reducible to less than or equal to 75 micrometers by mechanical grinding. Also disclosed is a method of making the friable polyimide powder, a processed polyimide resulting from the friable polyimide powder and compositions comprising the processed polyimide.

Abstract: A polyetherimide manufactured by reaction of an alkali metal salt of a dihydroxy aromatic compound with a bis(halophthalimide) composition comprising, based on the weight of the bis(halophthalimide) composition, from more than 45 to less than 75 weight percent of a 3,3?-bis(halophthalimide), less than 10 weight percent of a 3,4?-bis(halophthalimide), and from more than 45 to less than 75 weight percent of a (4,4?-bis(halophthalimide.

Abstract: A polyetherimide composition is disclosed including a polyetherimide sulfone having a glass transition temperature of 240 to 320 C, preferably 245 to 312 C, and a particulate, thermally conductive filler composition. A layer of the polyetherimide composition resists deformation as determined by IPC method TM-650 when subjected to a lead-free solder reflow process at a temperature of greater than or equal to 260 C, preferably 260 to 350 C. A layer including the polyetherimide composition further has a thermal conductivity of 2.5 to 15 W/mK, preferably 3 to 12 W/mK, as determined in accordance with ISO 22007-2:2008.

Abstract: A copolyester includes repeating units derived from an aliphatic glycol, terephthalic acid, and the monomer of formula (I): wherein n=2, 3 or 4; Z is C?O; comonomer (I) constitutes a proportion of the glycol fraction of the copolyester and is present in a range of from about 5 to about 15 mol % of the glycol fraction of the copolyester; wherein said copolyester is semi-crystalline. A process tor making the copolyester includes annealing a copolyester of formula (I) at 20-80° C. below the crystalline melting point (Tm) and above the glass transition temperature (Tg).

Abstract: A method of manufacturing polyimide particles includes combining a polyimide solution including a polyimide and an organic solvent with an aqueous solution including water in the presence of an emulsifying surfactant at a shear rate from 1,000 to 3,000 revolutions per minute to form an emulsion. The method further includes removing the organic solvent to form an aqueous polymer dispersion including polyimide particles, and recovering the polyimide particles. The polyimide particles have a spherical morphology and a volume based D10 diameter from 3 to 50 micrometers, a volume based D90 diameter from 3 to 80 micrometers, and a volume based D100 diameter from 3 to 100 micrometers.